The DREAMM-2 clinical trial evaluated the efficacy and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma who had received at least three prior lines of therapy, including an IMiD, a PI, and an anti-CD38 monoclonal antibody. The gene discussed is CD38; the disease is AL amyloidosis.